Elutia's Q2 revenue falls on SimpliDerm production disruption

Elutia

13/08/2026 21:18

Overview
US biomatrix developer's Q2 revenue declined yr/yr due to SimpliDerm production disruption
Net loss narrowed to $7.6 mln from $9.6 mln a year earlier
Company secured up to $26 mln in new capital without an equity offering

Outlook
Elutia expects FDA clearance decision for NXT-41 in 4Q 2026
Company anticipates NXT-41x FDA clearance decision in 1H 2027
Elutia plans full commercial launch of NXT-41x in 2028

Result Drivers
SIMPLIDERM DISRUPTION - Revenue fell due to a $0.7 mln reduction in SimpliDerm sales from a contract manufacturing production disruption
LITIGATION COSTS - Operating expenses decreased, driven by a $1.9 mln reduction in net litigation costs
R&D SPENDING - Research and development expenses rose $1.5 mln to support NXT-41 and NXT-41x programs

Company press release: ID:nGNX5V5d3k

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$2.43 mln
$2.90 mln (1 Analyst)
Q2 Loss Per Share
 
$0.17
 
Q2 Net Loss
 
$7.65 mln
 
Q2 Gross Profit
 
$1.45 mln
 
Q2 Income From Operations
 
-$7.96 mln
 
Q2 Operating Expenses
 
$9.4 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Elutia Inc is $5.00, about 511.2% above its August 12 closing price of $0.82

Reuters Recommended Reads
Aug 11 - Xtant Medical Q2 revenue falls on asset sales and lost license revenue
Aug 13 - Switzerland's Kuros Biosciences swing to H1 profit as revenue jumps
Aug 13 - Biofrontera Q2 revenue rises on higher volume, pricing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)